A closer look at chemotherapy‐induced flagellate dermatitis

Abstract Background Flagellate dermatitis (FD) is a rare skin rash, which may occur following the administration of antineoplastic agents. It has been reported following the administration of bleomycin, docetaxel, trastuzumab, cisplatin, bendamustine and doxorubicin. We provide a summary of the epid...

Full description

Bibliographic Details
Main Authors: A. Constantinou, D. Kotecha, P. Laouris, B. dePaula
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Skin Health and Disease
Online Access:https://doi.org/10.1002/ski2.92
_version_ 1811185635974709248
author A. Constantinou
D. Kotecha
P. Laouris
B. dePaula
author_facet A. Constantinou
D. Kotecha
P. Laouris
B. dePaula
author_sort A. Constantinou
collection DOAJ
description Abstract Background Flagellate dermatitis (FD) is a rare skin rash, which may occur following the administration of antineoplastic agents. It has been reported following the administration of bleomycin, docetaxel, trastuzumab, cisplatin, bendamustine and doxorubicin. We provide a summary of the epidemiology, aetiology, pathophysiology, and distribution of chemotherapy‐induced FD. Methods PubMed was searched using ((flagellat*) AND (Dermat*)) OR ((Flagellat*) AND (Erythema)). The search yielded 206 publications, out of which 54 individual case reports were identified which fulfilled our inclusion criteria. Statistical analysis was performed where appropriate. Results Female patients were slightly more likely to develop FD compared to males. In the majority of cases FD appeared on the upper and lower limbs and pruritus was an accompanying feature in 51% of cases. Most cases developed after the first cycle of chemotherapy and females were statistically more likely to present within the first 72 hr (p <0.05). Skin biopsies were taken in 41% of cases and this was not statistically associated with the patient’s gender, (p = 0.651), presentation within 72 hr (p = 0.076) or cancer diagnosis. Chemotherapy was stopped in 62% of patients and was associated with female gender (p = 0.0098). Most patients who received treatment were managed with topical steroids. Time for rash resolution ranged from a few weeks to four months following the discontinuation of the causative drug. Conclusion FD is a rare adverse skin effect of chemotherapeutic treatment, most commonly presenting on the upper and lower limbs of patients following their first cycle of chemotherapy. Early presentation is more common in females leading to increased likelihood of stopping chemotherapy. Biopsy findings poorly correlate with disease severity. Continuation of chemotherapy treatment in combination with topical steroids may not adversely affect rash resolution.
first_indexed 2024-04-11T13:32:36Z
format Article
id doaj.art-cf0e9a998d64435881a01d4c12f110f3
institution Directory Open Access Journal
issn 2690-442X
language English
last_indexed 2024-04-11T13:32:36Z
publishDate 2022-03-01
publisher Wiley
record_format Article
series Skin Health and Disease
spelling doaj.art-cf0e9a998d64435881a01d4c12f110f32022-12-22T04:21:45ZengWileySkin Health and Disease2690-442X2022-03-0121n/an/a10.1002/ski2.92A closer look at chemotherapy‐induced flagellate dermatitisA. Constantinou0D. Kotecha1P. Laouris2B. dePaula3School of Clinical Medicine University of Cambridge Cambridge UKSchool of Clinical Medicine University of Cambridge Cambridge UKSchool of Clinical Medicine University of Cambridge Cambridge UKDepartment of Oncology University of Cambridge Cambridge UKAbstract Background Flagellate dermatitis (FD) is a rare skin rash, which may occur following the administration of antineoplastic agents. It has been reported following the administration of bleomycin, docetaxel, trastuzumab, cisplatin, bendamustine and doxorubicin. We provide a summary of the epidemiology, aetiology, pathophysiology, and distribution of chemotherapy‐induced FD. Methods PubMed was searched using ((flagellat*) AND (Dermat*)) OR ((Flagellat*) AND (Erythema)). The search yielded 206 publications, out of which 54 individual case reports were identified which fulfilled our inclusion criteria. Statistical analysis was performed where appropriate. Results Female patients were slightly more likely to develop FD compared to males. In the majority of cases FD appeared on the upper and lower limbs and pruritus was an accompanying feature in 51% of cases. Most cases developed after the first cycle of chemotherapy and females were statistically more likely to present within the first 72 hr (p <0.05). Skin biopsies were taken in 41% of cases and this was not statistically associated with the patient’s gender, (p = 0.651), presentation within 72 hr (p = 0.076) or cancer diagnosis. Chemotherapy was stopped in 62% of patients and was associated with female gender (p = 0.0098). Most patients who received treatment were managed with topical steroids. Time for rash resolution ranged from a few weeks to four months following the discontinuation of the causative drug. Conclusion FD is a rare adverse skin effect of chemotherapeutic treatment, most commonly presenting on the upper and lower limbs of patients following their first cycle of chemotherapy. Early presentation is more common in females leading to increased likelihood of stopping chemotherapy. Biopsy findings poorly correlate with disease severity. Continuation of chemotherapy treatment in combination with topical steroids may not adversely affect rash resolution.https://doi.org/10.1002/ski2.92
spellingShingle A. Constantinou
D. Kotecha
P. Laouris
B. dePaula
A closer look at chemotherapy‐induced flagellate dermatitis
Skin Health and Disease
title A closer look at chemotherapy‐induced flagellate dermatitis
title_full A closer look at chemotherapy‐induced flagellate dermatitis
title_fullStr A closer look at chemotherapy‐induced flagellate dermatitis
title_full_unstemmed A closer look at chemotherapy‐induced flagellate dermatitis
title_short A closer look at chemotherapy‐induced flagellate dermatitis
title_sort closer look at chemotherapy induced flagellate dermatitis
url https://doi.org/10.1002/ski2.92
work_keys_str_mv AT aconstantinou acloserlookatchemotherapyinducedflagellatedermatitis
AT dkotecha acloserlookatchemotherapyinducedflagellatedermatitis
AT plaouris acloserlookatchemotherapyinducedflagellatedermatitis
AT bdepaula acloserlookatchemotherapyinducedflagellatedermatitis
AT aconstantinou closerlookatchemotherapyinducedflagellatedermatitis
AT dkotecha closerlookatchemotherapyinducedflagellatedermatitis
AT plaouris closerlookatchemotherapyinducedflagellatedermatitis
AT bdepaula closerlookatchemotherapyinducedflagellatedermatitis